Fabio Chianelli

Part of Revive Therapeutics Ltd., Revive Therapeutics, Inc. is a specialty life sciences company based in North York, CA. The company focuses on the research and development of therapeutics for rare disorders and infectious diseases. Revive Therapeutics' cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas such as liver disease. Revive Therapeutics was acquired by Mercury Capital II Ltd. on January 06, 2014 for $4.67 million. The Canadian company was granted FDA orphan drug status designation for the use of CBD to treat auto-immune hepatitis and ischemia and reperfusion injury from organ transplantation. The company is also exploring the use of bucillamine for the potential treatment of infectious diseases, including COVID-19. The company was founded by Fabio Chianelli. Revive recently acquired Psilocin Pharma Corp. to advance psilocybin-based therapeutics in various diseases and disorders.